PCM
AKBA icon

Prelude Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Prelude Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,000
Closed -$23.8K – 1197
2024
Q1 		$23.8K Buy
+13,000
New +$20.8K ﹤0.01% 1276

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's AKBA Position: Q4 2025 in Review

Prelude Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 32,840 shares — an estimated $89.7K sold.

Prelude Capital Management first reported a position in AKBA in Q4 2016 and held it in 11 quarters. The position peaked at $250K in Q1 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Prelude Capital Management reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 32,840 Akebia Therapeutics shares in Q4 2025, an estimated $89.7K.
  • Prelude Capital Management first reported a position in Akebia Therapeutics in Q4 2016 and held it in 11 quarters.
  • Prelude Capital Management's Akebia Therapeutics position peaked at $250K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.